Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of irinotecan liposome injection in advanced biliary tract cancer
CTR20212885Phase 2Terminated
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Nov 2021
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan liposome in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA), gallbladder cancer, sponsored by CSPC Ouyi Pharmaceutical. Started Nov 2021; status: terminated.
02
Drugs
irinotecan liposome
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on CTR20212885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212885.